AbbVie (ABBV), Boehringer Ingelheim Enter Agreement for BI 655066 Development, Commercialization
Tweet Send to a Friend
AbbVie (NYSE: ABBV) and Boehringer Ingelheim announced a global collaboration to develop and commercialize BI 655066, an anti-IL-23 monoclonal biologic ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
